1. Nebivolol Sensitizes BT-474 Breast Cancer Cells to FGFR Inhibitors.
- Author
-
Kim YJ, Jang SK, Kim G, Hong SE, Park CS, Seong MK, Kim HA, Kim KS, Kim CH, Park KS, Hong J, Jin HO, and Park IC
- Subjects
- Humans, Female, Nebivolol pharmacology, Nebivolol therapeutic use, Proto-Oncogene Proteins c-akt metabolism, Receptors, Fibroblast Growth Factor metabolism, Signal Transduction, Protein Kinase Inhibitors pharmacology, Cell Line, Tumor, Breast Neoplasms drug therapy, Breast Neoplasms genetics
- Abstract
Background/aim: The fibroblast growth factor receptor (FGFR) signaling pathway is abnormally activated in human cancers, including breast cancer. Therefore, targeting the FGFR signaling pathway is a potent strategy to treat breast cancer. The purpose of this study was to find drugs that could increase sensitivity to FGFR inhibitor effects in BT-474 breast cancer cells, and to investigate the combined effects and underlying mechanisms of these combinations for BT-474 breast cancer cell survival., Materials and Methods: Cell viability was measured by MTT assay. Protein expression was determined by western blot analysis. mRNA expression was detected by Real-time PCR. Drug synergy effect was determined by isobologram analysis., Results: Nebivolol, a third generation β1-blocker, synergistically increased the sensitivity of BT-474 breast cancer cells to the potent and selective FGFR inhibitors erdafitinib (JNJ-42756493) and AZD4547. A combination of nebivolol and erdafitinib markedly reduced AKT activation. Suppression of AKT activation using specific siRNA and a selective inhibitor further enhanced cell sensitivity to combined treatment with nebivolol and erdafitinib, whereas SC79, a potent activator of AKT, reduced cell sensitivity to nebivolol and erdafitinib., Conclusion: Enhanced sensitivity of BT-474 breast cancer cells to nebivolol and erdafitinib was probably associated with down-regulation of AKT activation. Combined treatment with nebivolol and erdafitinib is a promising strategy for breast cancer treatment., (Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF